BS-HH-002
Phase 1- Indications
- Pancreatic cancer, Acute myeloid leukemia, Myelodysplastic syndromes
Company intelligence / Profile preview
Hangzhou Bensheng Pharmaceutical Co Ltd
Hangzhou, Zhejiang Sheng, Chinapubmed.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Hangzhou Bensheng Pharmaceutical develops small molecule therapeutics targeting oncology and hematology indications. Its lead candidate, BS-HH‑002, is an Mcl‑1 inhibitor in Phase 1 trials for acute myeloid leukemia and other cancers. Other pipeline assets are at preclinical or pending stages.
- Therapeutic areas
- OncologyHematology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Hangzhou Bensheng Pharmaceutical Co Ltd.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hangzhou Bensheng Pharmaceutical Co Ltd.